Chih-Hsin Lin

Chih-Hsin Lin

Auto-generated profile, based on publicly available information

Chih-Hsin Lin

Department of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taoyuan 33302, Taiwan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CCChiung-Mei Chen
Chiung-Mei Chen
CYChien-Yu Yen
Chien-Yu Yen
WCWan-Ling Chen
Wan-Ling Chen
YWYih Ru Wu
Yih Ru Wu
KCKuo-Hsuan Chang
Kuo-Hsuan Chang
GLGuey-Jen Lee-Chen
Guey-Jen Lee-Chen
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic (DAergic) neurons and the presence of α-synuclein-containing Lewy bodies. The unstructured α-synuclein forms insoluble fibrils and aggregates that result in increased reactive oxygen species (ROS) and cellular toxicity in PD. Neuroinflammation engaged by microglia actively contributes to the pathogenesis of PD. In this study, we showed that VB-037 (a quinoline compound), glycyrrhetic acid (a pentacyclic triterpenoid), Glycyrrhiza inflata (G. inflata, a Chinese herbal medicine), and Shaoyao Gancao Tang (SG-Tang, a formulated Chinese medicine) suppressed the nitric oxide (NO) production and interleukin (IL)-1β maturation in α-synuclein-stimulated BV-2 cells. Mouse inflammation antibody array further revealed increased IL-1α, IL-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) expression in α-synuclein-inflamed BV-2 cells and compound pretreatment effectively reduced the expression and release of these pro-inflammatory mediators. The test compounds and herbal medicines further reduced α-synuclein aggregation and associated oxidative stress, and protected cells against α-synuclein-induced neurotoxicity by downregulating NLR family pyrin domain containing 1 (NLRP1) and 3 (NLRP3), caspase 1, IL-1β, IL-6, and associated nuclear factor (NF)-κB inhibitor alpha (IκBα)/NF-κB P65 subunit (P65), c-Jun N-terminal kinase (JNK)/proto-oncogene c-Jun (JUN), mitogen-activated protein kinase 14 (P38)/signal transducer and activator of transcription 1 (STAT1) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathways in dopaminergic neurons derived from α-synuclein-expressing SH-SY5Y cells. Our findings indicate the potential of VB-037, glycyrrhetic acid, G. inflata, and SG-Tang through mitigating α-synuclein-stimulated neuroinflammation in PD, as new drug candidates for PD treatment.

16 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
CCChiung-Mei Chen
Chiung-Mei Chen
CLChih-Hsin Lin
Chih-Hsin Lin
YWYih Ru Wu
Yih Ru Wu
CYChien-Yu Yen
Chien-Yu Yen
YHYu-Ting Huang
Yu-Ting Huang
KCKuo-Hsuan Chang
Kuo-Hsuan Chang
Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra (SN) and proteinaceous α-synuclein-positive Lewy bodies and Lewy neuritis. As a chemical chaperone to promote protein stability and an autophagy inducer to clear aggregate-prone proteins, a disaccharide trehalose has been reported to alleviate neurodegeneration in PD cells and mouse models. Its trehalase-indigestible analogs, lactulose and melibiose, also demonstrated potentials to reduce abnormal protein aggregation in spinocerebellar ataxia cell models. In this study, we showed the potential of lactulose and melibiose to inhibit α-synuclein aggregation using biochemical thioflavin T fluorescence, cryogenic transmission electron microscopy (cryo-TEM) and prokaryotic split Venus complementation assays. Lactulose and melibiose further reduced α-synuclein aggregation and associated oxidative stress, as well as protected cells against α-synuclein-induced neurotoxicity by up-regulating autophagy and nuclear factor, erythroid 2 like 2 (NRF2) pathway in DAergic neurons derived from SH-SY5Y cells over-expressing α-synuclein. Our findings strongly indicate the potential of lactulose and melibiose for mitigating PD neurodegeneration, offering new drug candidates for PD treatment.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YCYa-Jen Chiu
Ya-Jen Chiu
TLTe-Hsien Lin
Te-Hsien Lin
CCChiung-Mei Chen
Chiung-Mei Chen
CLChih-Hsin Lin
Chih-Hsin Lin
YTYu-Shan Teng
Yu-Shan Teng
KCKuo-Hsuan Chang
Kuo-Hsuan Chang
Abnormal accumulations of misfolded Aβ and tau proteins are major components of the hallmark plaques and neurofibrillary tangles in the brains of Alzheimer’s disease (AD) patients. These abnormal protein deposits cause neurodegeneration through a number of proposed mechanisms, including downregulation of the cAMP‐response‐element (CRE) binding protein 1 (CREB) signaling pathway. Using CRE‐GFP reporter cells, we investigated the effects of three coumarin‐chalcone derivatives synthesized in our lab on CREB‐mediated gene expression. Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells were used to evaluate these agents for possible antiaggregative, antioxidative, and neuroprotective effects. Blood‐brain barrier (BBB) penetration was assessed by pharmacokinetic studies in mice. Of the three tested compounds, (E)‐3‐(3‐(4‐(dimethylamino)phenyl)acryloyl)‐4‐hydroxy‐2H‐chromen‐2‐one (LM‐021) was observed to increase CREB‐mediated gene expression through protein kinase A (PKA), Ca2+/calmodulin‐dependent protein kinase II (CaMKII), and extracellular signal‐regulated kinase (ERK) in CRE‐GFP reporter cells. LM‐021 exhibited antiaggregative, antioxidative, and neuroprotective effects mediated by the upregulation of CREB phosphorylation and its downstream brain‐derived neurotrophic factor and BCL2 apoptosis regulator genes in Aβ‐GFP‐ and ΔK280 tauRD‐DsRed‐expressing SH‐SY5Y cells. Blockage of the PKA, CaMKII, or ERK pathway counteracted the beneficial effects of LM‐021. LM‐021 also exhibited good BBB penetration ability, with brain to plasma ratio of 5.3%, in in vivo pharmacokinetic assessment. Our results indicate that LM‐021 works as a CREB enhancer to reduce Aβ and tau aggregation and provide neuroprotection. These findings suggest the therapeutic potential of LM‐021 in treating AD.

4 June 2020 in Aging Cell
Verified
Journal Article
Open access
PDF file
TLTe‐Hsien Lin
Te‐Hsien Lin
YCYa-Jen Chiu
Ya-Jen Chiu
CLChih‐Hsin Lin
Chih‐Hsin Lin
Chung-Yin LinChung-Yin Lin
Chung-Yin Lin
CCChih‐Ying Chao
Chih‐Ying Chao
CCChiung-Mei Chen
Chiung-Mei Chen
Microtubule‐associated protein Tau, abundant in the central nervous system (CNS), plays crucial roles in microtubule assembly and stabilization. Abnormal Tau phosphorylation and aggregation are a common pathogenic hallmark in Alzheimer's disease (AD). Hyperphosphorylation of Tau could change its conformation and result in self‐aggregation, increased oxidative stress, and neuronal death. In this study, we examined the potential of licochalcone A (a natural chalcone) and five synthetic derivatives (LM compounds) for inhibiting Tau misfolding, scavenging reactive oxygen species (ROS) and providing neuroprotection in human cells expressing proaggregant ΔK280 TauRD‐DsRed. All test compounds were soluble up to 100 μM in cell culture media and predicted to be orally bioavailable and CNS‐active. Among them, licochalcone A and LM‐031 markedly reduced Tau misfolding and associated ROS, promoted neurite outgrowth, and inhibited caspase 3 activity in ΔK280 TauRD‐DsRed 293 and SH‐SY5Y cells. Mechanistic studies showed that LM‐031 upregulates HSPB1 chaperone, NRF2/NQO1/GCLC pathway, and CREB‐dependent BDNF/AKT/ERK/BCL2 pathway in ΔK280 TauRD‐DsRed SH‐SY5Y cells. Decreased neurite outgrowth upon induction of ΔK280 TauRD‐DsRed was rescued by LM‐031, which was counteracted by knockdown of NRF2 or CREB. LM‐031 further rescued the downregulated NRF2 and pCREB, reduced Aβ and Tau levels in hippocampus and cortex, and ameliorated cognitive deficits in streptozocin‐induced hyperglycemic 3 × Tg‐AD mice. Our findings strongly indicate the potential of LM‐031 for modifying AD progression by targeting HSPB1 to reduce Tau misfolding and activating NRF2 and CREB pathways to suppress apoptosis and promote neuron survival, thereby offering a new drug development avenue for AD treatment.

27 October 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YWYih Ru Wu
Yih Ru Wu
CLChih-Hsin Lin
Chih-Hsin Lin
CCChih-Ying Chao
Chih-Ying Chao
CCChia-Wen Chang
Chia-Wen Chang
CCChiung-Mei Chen
Chiung-Mei Chen
GLGuey-Jen Lee-Chen
Guey-Jen Lee-Chen
Sequence variants in vacuolar protein sorting 35 (VPS35) have been reported to be associated with Parkinson’s disease (PD). To investigate if the genetic variants in VPS35 contribute to Taiwanese PD, VPS35 cDNA fragments from 62 patients with PD were sequenced. A cohort of PD (n = 560) and ethnically matched controls (n = 506) were further examined for the identified mutation. The effects of the mutation on cation-independent mannose-6-phosphate receptor (CI-MPR) sorting and mitochondrial morphology were further examined in 293T cells expressing the mutant VPS35. Here, a novel heterozygous A320V in the VPS35 gene was identified in two late-onset PD (LOPD) patients, which was absent in 506 normal controls. Expression of the A320V mutant in 293T cells demonstrated increased colocalization of VPS35 with CI-MPR and decreased CI-MPR and lysosomal-associated membrane protein 2 (LAMP2) levels. Decreased CI-MPR manifested in missorting of cathepsin D and decreased proteolysis of α-synuclein. A320V mutation also increased mitochondrial E3 ubiquitin protein ligase 1 (MUL1) and thus led to mitofusin 2 (MFN2) degradation. The results suggest that the expression of VPS35 A320V leads to disrupted CI-MPR sorting and impaired mitochondrial morphology, which may partly explain its action in PD.

9 September 2026 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
CLChih-Hsin Lin
Chih-Hsin Lin
YWYih Ru Wu
Yih Ru Wu
CCChih-Ying Chao
Chih-Ying Chao
CCChiung-Mei Chen
Chiung-Mei Chen
ICI-Cheng Chen
I-Cheng Chen
KCKuo-Hsuan Chang
Kuo-Hsuan Chang